Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.